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ARTICLE
Autosomal-Dominant Corneal Endothelial Dystrophies
CHED1 and PPCD1 Are Allelic Disorders Caused
by Non-coding Mutations in the Promoter of OVOL2
Alice E. Davidson,1,9 Petra Liskova,1,2,3,9,* Cerys J. Evans,1,9 Lubica Dudakova,2 Lenka Noskova´,2
Nikolas Pontikos,1,4 Hana Hartmannova´,2 Katerina Hodanova´,2 Viktor Stra´necky´,2 Zbynek Kozmı´k,5
Hannah J. Levis,1 Nwamaka Idigo,1 Noriaki Sasai,1 Geoffrey J. Maher,6 James Bellingham,1 Neyme Veli,7
Neil D. Ebenezer,1 Michael E. Cheetham,1 Julie T. Daniels,1 Caroline M.H. Thaung,1,7 Katerina Jirsova,2
Vincent Plagnol,4 Martin Filipec,8 Stanislav Kmoch,2 Stephen J. Tuft,1,7 and Alison J. Hardcastle1,*
Congenital hereditary endothelial dystrophy 1 (CHED1) and posterior polymorphous corneal dystrophy 1 (PPCD1) are autosomal-domi-
nant corneal endothelial dystrophies thathavebeengeneticallymapped tooverlapping loci on the short armof chromosome20.We com-
bined genetic and genomic approaches to identify the cause of disease in extensive pedigrees comprising over 100 affected individuals.
After exclusion of pathogenic coding, splice-site, and copy-number variations, a parallel approach using targeted and whole-genome
sequencing facilitated the identification of pathogenic variants in a conserved region of the OVOL2 proximal promoter sequence in
the index families (c.339_361dup for CHED1 and c.370T>C for PPCD1). Direct sequencing of theOVOL2promoter in other unrelated
affected individuals identified two additional mutations within the conserved proximal promoter sequence (c.274T>G and
c.307T>C).OVOL2 encodesovo-like zincfinger2, aC2H2zinc-finger transcription factor that regulatesmesenchymal-to-epithelial tran-
sition and acts as a direct transcriptional repressor of the established PPCD-associated gene ZEB1. Interestingly, we did not detectOVOL2
expression in thenormal corneal endothelium.Our invitrodatademonstrate that all fourmutatedOVOL2promoters exhibitedmore tran-
scriptional activity than the corresponding wild-type promoter, and we postulate that the mutations identified create cryptic cis-acting
regulatory sequence binding sites that drive aberrant OVOL2 expression during endothelial cell development. Our data establish
CHED1 and PPCD1 as allelic conditions and show that CHED1 represents the extreme of what can be considered a disease spectrum.
They also implicate transcriptional dysregulation ofOVOL2 as a common cause of dominantly inherited corneal endothelial dystrophies.Introduction
Posterior polymorphous corneal dystrophy (PPCD) is an
autosomal-dominant disease that primarily affects the
corneal endothelium. PPCD is characterized by abnormal
corneal endothelial cell morphology and associated Desce-
met membrane changes, which produce the appearance of
vesicular lesions, gray-white opacities, and linear bands
on clinical examination of the cornea.1 The altered
morphology is most likely congenital and either static or
slowly progressive throughout life. There could also be
iris abnormalities, such as ectropion uveae, corectopia,
and adhesions, between the peripheral iris and the poste-
rior surface of the cornea.2,3 The disease is associated
with a broad phenotypic spectrum ranging from mild
symptoms to congenital corneal edema. In a minority of
cases, these changes lead to a raised intraocular pressure
with secondary glaucoma.2,4,5 Up to 33% of PPCD subjects
require corneal grafting to treat their corneal edema.6,7
PPCD is genetically heterogeneous, and approximately
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The Atruncating mutations or deletions of the transcription-fac-
tor-encoding gene ZEB1 (MIM: 189909). These mutations
cause PPCD3 (MIM: 609141).8–10 Non-synonymous vari-
ants in COL8A2 (MIM: 120252) are also reportedly associ-
ated with PPCD in a minority of cases (PPCD2 [MIM:
609140]).11 The majority of genetically unsolved cases
are most likely associated with a third PPCD locus
(PPCD1 [MIM: 122000]), which was originally mapped to
a 30 cM region on the short arm of chromosome 20
(20p).7 The PPCD1 locus was subsequently refined in two
large families of Czech origin6,12 and a large white Amer-
ican family.5,13,14
The phenotypes described as PPCD1 share similarities
with an autosomal-dominant corneal endothelial dystro-
phy with a severe phenotype originally termed congenital
hereditary corneal edema and subsequently classified as
congenital hereditary endothelial dystrophy 1 (CHED1
[MIM: 121700]).1,4 However, differences have also been
reported.Notably, individuals in the indexCHED1-affected
family presented with a very severe phenotype often
including corneal haze that was evident by 1 year of age9EL, UK; 2Institute of Inherited Metabolic Disorders, First Faculty of Medi-
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Figure 1. Pedigree Structure of CHED1- and PPCD1-Affected Families with OVOL2 Promoter Mutations
Pedigrees of (A) the index British CHED1-affected family (BR1), (B) 16 PPCD1-affected families (C1–C14, C25, and C30) from the Czech
Republic, and further British families (C) BR2 and (D) BR3. For each family (BR1–BR3) or group of families (C1–C14, C25, and C30), a
distinct and unique mutation in the OVOL2 promoter was identified. Sanger sequencing traces representing the four unique
(legend continued on next page)
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and required corneal transplantation.1,15 Linkage analysis
of this large British kindred mapped the disease to a
2.7 Mb locus on 20p, but the genetic cause has not been
determined.16 Because PPCD1 and CHED1map to overlap-
ping loci on 20p, it is speculated that these two disorders
could be allelic conditions that are caused by mutations
within the same gene but that display variable phenotypic
severity.Alternatively, they couldbe causedbymutations in
two different genes at neighboring loci.1,12–14,16,17
In this article, we describe sequential genetic analyses
that excluded copy-number variations (CNVs) and coding
and/or splice-site mutations as the cause of CHED1 or
PPCD1, andwe also identify the cause of disease via a paral-
lel approach of genome sequence analysis. We show that
variants in the OVOL2 promoter sequence cause the spec-
trum of phenotypes observed in over 100 affected individ-
uals, implicating perturbed transcriptional regulation of
OVOL2 as a major cause of dominant corneal endothelial
dystrophies.Material and Methods
Study Subjects and Clinical Examination
The study followed the tenets of the Declaration of Helsinki and
was approved by the research ethics committees (RECs) at Moor-
fields Eye Hospital (REC reference nos. 13/LO/1084 and 09/
H0724/25) and the General University Hospital in Prague. After
informed consent was obtained, blood samples were donated,
and genomic DNA was extracted from lymphocytes or saliva sam-
ples via conventional methodologies.
A detailed history was recorded and ophthalmic examination
was performed for all available study subjects (highlighted in
Figure 1). Specular microscopy (Noncon ROBO Pachy SP-9000,
Konan Medical) and spectral-domain optical coherence tomogra-
phy (SPECTRALIS, Heidelberg Engineering) were performed in
select cases.Histology
Full-thickness corneas from individuals VII:13 (age 6 years) and
VII:7 (age 11 years) from family BR1 and individual III:1 (age 42
years) from family C11 were fixed in 10% neutral-buffered
formalin and 10% formalin, respectively. Samples were then pro-
cessed into paraffin wax, and 4 mm (VII:13 and VII:7) or 6 mm
(III:1) sections were cut. Samples from individuals VII:13 and
VII:7 (family BR1) were stained with H&E and PAS stains via con-
ventional methods. The sample from individual III:1 from family
C11 was stained with H&E only.CNVAnalysis
Array comparative genomic hybridization (CGH) was used for
evaluating DNA CNVs on chromosome 20. DNA from affected in-heterozygous mutations identified are shown in each respective p
Mutations are annotated in accordance with GenBank: NM_02122
ATG translation initiation codon. DNA from individuals, each high
of the disease-associated locus (chr20: 17,335,789–19,665,902). Aster
breviations are as follows: W, whole-exome sequencing (WES); and
genome sequenced.
The Adividual VII:13 from family BR1 was hybridized (labeled with
Cy3) to a dense chromosome 20 array (median probe spacing
of 1 per 134 bp, NimbleGen Systems) with a reference DNA sam-
ple (labeled with Cy5). The data were visualized with SignalMap
software (NimbleGen Systems). DNA from individuals III:19
(affected) and III:16 (unaffected spouse) from family C1 was
also previously analyzed via the same methodology.12 In addi-
tion, data from both SNP and copy-number probes present on
Affymetrix Genome-Wide Human SNP Array 6.0 were used for
identifying copy-number changes in five members from the
Czech familial cohort (individuals IV:16, IV:17, V:9, V:10, and
V:11 from family C2) in accordance with previously described
methods.18,19Haplotype Analysis
Haplotype analysis was performed in family BR1 with the aim of
refining the previously identified region of linkage.16 A com-
bination of SNP and microsatellite markers were genotyped via
conventional PCR and direct Sanger sequencing (Figure S1 and
Table S1; primer sequences are available upon request). Fluores-
cently labeled microsatellite markers from the ABI Prism Linkage
Mapping Set v.2.5 (Applied Biosystems) were used for genotyping
microsatellites. PCR-amplified products were analyzed on an
ABI Prism 3100 Genetic Analyzer (Applied Biosystems), and
GeneMarker v.1.85 software was used for generatingmicrosatellite
genotyping calls.Whole-Exome Sequencing
Individuals VII:13 and VI:5 from family BR1 were analyzed by
whole-exome sequencing (WES) on a SureSelect XT2 Human All
Exon v.4.0 capture kit (Agilent) and a HiSeq 2000 sequencer (Illu-
mina). Reads were aligned to the human reference sequence
(UCSCGenome Browser hg19) with Novoalign v.2.05 (Novocraft).
ANNOVAR (OpenBioinformatics) was used for annotating SNPs
and small indels. ExomeDepth20 was used for calling CNVs.
Aligned data were visualized with the Integrated Genomics Viewer
(Broad institute).
In parallel, pooled DNA samples from ten affected individuals
from the Czech familial cohort (highlighted in Figure 1B: IV:3
and V:5 from family C1, IV:8 and V:9 from family C2, III:5
from family C3, IV:6 from family C6, IV:1 from family C9,
III:1 from family C11, IV:6 from family C13, and II:3 from family
C25) were enriched with SeqCap V3 (NimbleGen) and
sequenced on an Illumina HiSeq 1500 system at the University
Hospital in Motol (Prague). The resulting FASTQ files were
aligned to the human reference genome (UCSC Genome Browser
hg19) with Novoalign. After genome alignment, conversion of
SAM format to BAM and duplicate removal were performed
with Picard Tools (v.1.129). The Genome Analysis Toolkit
(GATK v.3.3) was used for local realignment around indels,
base recalibration, and variant recalibration and genotyping.
Variants were annotated with SnpEff21 and GEMINI,22 and
CNVs were identified from exome read counts with CoNIFER
(v.0.2.2.).22anel (A–D). Second-degree unaffected relatives are not shown.
0 (Ensembl: ENST00000278780), and þ1 represents the A of the
lighted with a red arrow, was analyzed by targeted re-sequencing
isks indicate that a DNA sample was available for genotyping. Ab-
pw, pooled WES. Dashed lines indicate that a sample was whole-
merican Journal of Human Genetics 98, 75–89, January 7, 2016 77
Targeted Capture and Sequencing of the PPCD1 Locus
A custom Sequence Capture 385K Human Array targeting the
PPCD1 linkage region on chromosome 20 between D20S48 and
D20S1076 was designed and manufactured by Roche NimbleGen.
DNA enrichment from approximately 20 mg of DNA from affected
individual V:11 and unaffected sibling V:10 from family C2 was
performed at NimbleGen Customer Service. Sequencing was per-
formed on a Roche 454 FLX instrument at the Institute of Molec-
ular Genetics in Prague according to the manufacturer’s protocol.
The reads were processed and aligned to the human reference
genome (UCSCGenome Browser hg19) with the Burrows-Wheeler
Aligner Smith-Waterman alignment (BWA-SW).23 Putative DNA
variants were detected with SAMtools (v.0.1.12). Unique DNA var-
iants were identified with SIFT 4.0.324 and SeattleSeq.
Whole-Genome Sequencing
DNA samples from affected individuals VII:3 and VI:24 and unaf-
fected individual VI:22 (age 44 years) from family BR1 were
analyzed by whole-genome sequencing (WGS) with a TruSeq
Nano DNA Library Preparation Kit (Illumina) and a HiSeq X Ten
sequencer (Illumina). Generated reads were aligned to the human
reference genome (UCSC Genome Browser hg38) with Novoalign.
Variant calling was performed with GATK (variants were first
called per individual sample with the GATKHaplotypeCaller mod-
ule, and then calls were improved with joint calling in the
GenotypeGVCFs module). Both coding and non-coding variants
were annotated with the Variant Effect Predictor (VEP). All vari-
ants were annotated with 1000 Genomes allele frequencies. Addi-
tionally, coding variants were annotated with allele frequencies
from the Exome Aggregation Consortium (ExAC) Browser. Vari-
ants were further annotated with Combined Annotation Depen-
dent Depletion (CADD), Combined Annotation Scoring Tool
(CAROL), and Consensus Deleteriousness (Condel) consequence
scores for assessment of their functional impact. Subsequently,
affected individual V:11 from family C2 was also analyzed by
WGS via the same methodology.
OVOL2 Sanger Sequencing
Members of families BR2 and BR3 were screened for OVOL2muta-
tions in the coding sequence, splice sites, and 1.8 kb of the pro-
moter region by direct Sanger sequencing from PCR amplimers
(primer sequences are available upon request) via conventional
methodologies. Segregation analysis of OVOL2 variants was also
performed by PCR amplification and direct Sanger sequencing in
families BR1, C1–C11, C13, C14, and BR3. Two hundred and
nine ethnically matched white British control DNA samples
were also screened for variants in the OVOL2 promoter region, en-
compassing all mutations identified in this study. In addition,
Czech control DNA samples were screened by PCR amplification
and restriction fragment digest using restriction enzyme Cfr13I
(Fermentas) as a test for the presence or absence of the
c.370T>C OVOL2 variant found in Czech PPCD1 individuals
(primers and reaction conditions are available upon request). All
OVOL2 variants are annotated in accordance with GenBank:
NM_021220, and þ1 represents the start of translation.
In Silico Analysis of Promoter Variants
Bioinformatic analyses of regulatory motifs and potential tran-
scription factor binding sites were compared between wild-type
and mutated promoter sequences with the programs Alibaba 2.1
and MatInspector.2578 The American Journal of Human Genetics 98, 75–89, January 7, 20Analysis of RNA-Sequencing Data
Human corneal endothelial RNA-sequencing (RNA-seq) reads
for three adult and two fetal (16- to 18-week-old) samples
(study SRP01140 from ArrayExpress) were aligned to the
human reference genome (NCBI Genome build GRCh38;
GCA_000001405.15_GRCh38 without alternate contigs; see
Web Resources) with STAR v.2.5.0. Duplicate reads were marked
with Picard MarkDuplicates v.1.100. Raw read counts, excluding
duplicate reads, were generated with DEXSeq python scripts
(dexseq_count.py). The resulting counts were normalized ac-
cording to the length of each feature (estimated with the Rsu-
bread package) and a library-size factor as estimated by the
DEXSeq tool. Gene annotations were based on Ensembl tran-
scripts and downloaded from the Ensembl page (GRCh38.82).Cell Culture, RNA Extraction, and RT-PCR
Whole human corneal tissue was donated after enucleation
surgery due to posterior segment melanoma. Corneal endothelial
tissue was also donated by individuals who had Descemet
membrane endothelial keratoplasty (DMEK) surgery for Fuchs
endothelial corneal dystrophy. Primary endothelial cells were
expanded and cultured in accordance with previously described
methods.26 An immortalized cell line of human corneal endothe-
lial origin, B4G12, was cultured according to published proto-
cols.27 Human stromal keratocytes were isolated from surgically
removed central graft tissue from a donor without any history of
ocular disease as described previously.28 Fibroblasts were derived
from expanding the cells in media supplemented with serum.28
Human corneoscleral rims stored in Optisol (Chiron Ophthal-
mics) from donors who provided research consent were obtained
from theMoorfields Eye Hospital tissue bank, and limbal epithelial
stem cells were isolated and cultured as previously described.29
HEK293 cells were cultured with standard reagents and
conditions.
Total RNA was extracted from cells or tissue with an RNeasy
Extraction Kit (QIAGEN) according to the manufacturer’s proto-
col. cDNA was reverse transcribed with a Tetro cDNA Synthesis
Kit (BIOLINE) and an oligo (dT)18 primer mix. For RT-PCR
reactions, OVOL2 was amplified with intron-spanning primers
50-CTCGCGATTTAAGGCATAGG-30 and 50-ACAGCTGTGAACCA
CCGAGT-30 from exons 1–3. Beta-actin was also amplified as a pos-
itive control with intron-spanning primers 50-CTGGGACGA
CATGGAGAAAA-30 (forward) and 50-AAGGAAGGCTGGAAGA
GTGC-30 (reverse).Luciferase Assay
Primers were designed to amplify a 1,824 bp fragment of the
OVOL2 promoter (chr20: 18,057,635–18,059,458) from control
human genomic DNA. The fragment was cloned into pGEM-T
Easy (Promega) and subsequently sub-cloned, with MluI and BglII
restriction sites, into the promoter-less firefly luciferase reporter
vector, pGL3-Basic (Promega), according to standard protocols
for the generation of pGL3-OVOL2. Variants of interest were intro-
duced into the OVOL2 promoter sequence by site-directed muta-
genesis with a Q5 Site-Directed Mutagenesis Kit (New England
Biolabs) in accordance with the manufacturer’s protocol. All con-
structs generated were Sanger sequenced for ensuring fidelity and
orientation (primers are available upon request).
HEK293 cells were seeded in 96-well plates and transfected at
80% confluency with TransIT-LT1 Transfection Reagent (Mirus).
Each well was transfected with a total of 100 ng of plasmid16
Figure 2. Spectrum of Corneal Disease
Associated with OVOL2 Mutations
(A–C) Individual VII:13 from family BR1 at
age 3 years. The right (A) and left (B) cor-
neas have a hazy appearance on direct illu-
mination and an increased thickness from
diffuse corneal edema. (C) A prominent De-
scemet membrane can be seen with nar-
row-beam illumination (arrow).
(D) Individual VI:2 from family BR1 at age
52 years (without surgery) shows secondary
lipoidal degeneration.
(E) Individual III:3 from family BR3 shows a
clear cornea but a distorted iris (arrow) sec-
ondary to the presence of a peripheral area
of iris-to-corneal adhesion (not shown).
(F–H) Histological specimens. (F) Individ-
uals VII:13 (age 6 years) and (G) VII:7 (age
11 years) from family BR1. Both individuals
have a thin and irregular Descemet mem-
brane (arrow), reduced endothelial cell
count (asterisks), and accumulation of ma-
terial posterior to the Descemet membrane,
possibly reflecting mild retrocorneal
fibrosis (double-headed arrow). (H) Individ-
ual III:1 from family C11 (42 years) shows
focal multilayering of endothelial cells (ar-
row) and undulation of the posterior
corneal surface.
(I) Retroillumination image of the cornea of
individual II:1 (age 29 years) from family
C30 shows a mild presentation. An island
of normally appearing endothelial cells is
surrounded by abnormal cells (arrows high-
light the boundary of cells with a normal
appearance).
(J and K) Individual III:5 (age 33 years) from
family C3. (J) A narrow-beam section of the
right cornea demonstrates a slight corneal haze and gray focal areas at the level of the Descemet membrane and endothelium (arrow-
head). (K) An ocular-coherence-tomography cross-section of the cornea demonstrates a raised lesion on the posterior corneal surface
(arrowhead).
(L and M) Corneal endothelial specular images from individual V:11 (age 13 years) from family C2. Note the variation in the individual
size and shape of the endothelial cells. The dark areas presumably correspond to elevated regions.
(N) For comparison, the corneal endothelial specular image of a 25-year-old unaffected sister of individual V:11 (V:10 from family C2)
shows a normal appearance of cells with a uniform size and shape.DNA, including 90 ng of pGL3-OVOL2 or pGL3-Control (the
SV40-enhancer- and promoter-containing positive control
construct), and 10 ng of the internal control pRL-CMV, a cytomeg-
alovirus (CMV)-promoter-driven Renilla luciferase reporter vector
(Promega). Twenty-four hours after transfection, luciferase activity
was measured on an Orion L Microplate Luminometer (Titertek
Berthol) with a dual-luciferase reporter assay system (Dual-Glo
Luciferase Assay System, Promega) in accordance with the manu-
facturer’s protocol.Results
Clinical Characterization of CHED1 and PPCD1
The clinical and histological features of disease in family
BR1 (Figure 1A) were first reported in 1969 as autosomal-
dominant congenital endothelial corneal dystrophy,4 and
further comments on selected individuals were provided
in 1987.15 The condition was subsequently mapped to a
2.7 Mb region on 20p between markers D20S48 andThe AD20S471 in 1995.16 Here, we re-visit this index family
(BR1), extend the pedigree, and provide a summary of the
phenotype (Figures 1A, 2A–2D, 2F, and 2G). The pedigree
now comprises 36 affected individuals spanning seven gen-
erations (Figure 1A). The disease appears to be fully pene-
trant and has no reported systemic associations. Affected
individuals typically show symptoms of epiphora and
photophobia from birth, and corneal haze is usually noted
by1yearof age.Raised intraocularpressureor iris abnormal-
itywasnotpresent in individuals prior to corneal transplan-
tation (Figures 2A–2D). Current data are available on 16
affected individuals from family BR1. All have received at
least one corneal graft, or keratoplasty (multiple transplants
were often needed after graft failure), as well as additional
surgeries for secondary glaucoma. Threehave alsohad a ker-
atoprosthesis (e.g., Boston keratoprosthesis), and three
have had an eye enucleated. Histological examination of
full-thickness corneas for two previously unreported
affected individuals, VII:13 (age 6 years) and VII:7 (age 11merican Journal of Human Genetics 98, 75–89, January 7, 2016 79
years), revealed a thin and irregular Descemet membrane,
reduced endothelial cell count, and accumulation of mate-
rial posterior to the Descemet membrane, possibly reflect-
ing mild retrocorneal fibrosis (Figures 2F and 2G).
Previous haplotype, geographic, and statistical analyses
demonstrated that unknowingly related PPCD1-affected
families from the southwestern region of the Czech Repub-
lic (around the town of Klatovy) harbor an undiscovered
mutation on 20p11.23 and that this mutation most likely
arose in a common ancestor originating more than 64 gen-
erations ago.12 The number of PPCD1-affected pedigrees
originating from this region of the Czech Republic (these
families constitute those described here) has been
extended and is represented in Figure 1B. Sixteen pedigrees
with over 100 affected individuals were identified. PPCD1
in this cohort is fully penetrant and has no reported sys-
temic associations. Affected members of these families pre-
sent with irregularities of the otherwise smooth posterior
corneal surface and often have focal opacities and
geographic lesions of abnormally appearing cells (Figures
2I–2K). The corneal endothelium exhibits occasional
multi-layering30 (Figure 2H). Microscopic visualization of
the specular reflection from the posterior corneal surface
further documents abnormal endothelial cell morphology
and irregularities of the posterior corneal surface (Figures
2L and 2M). One-third of these subjects have had a kerato-
plasty in at least one eye. Additionally, approximately
30%, including some individuals who had not had corneal
transplantation, show secondary glaucoma. The pheno-
type, including the necessity for keratoplasty and occur-
rence of secondary glaucoma for some affected individuals,
has been described previously.6,31 In contrast to family
BR1, none of the affected members had corneal edema pre-
sent at birth; the earliest manifestation was in two 5-year-
old children (individuals III:3 C5 and IV:2 from C6), which
is exceptionally early in this cohort. Out of 75 genotyped
Czech PPCD1 individuals, only six underwent keratoplasty
before the age of 18 years.
To identify the genetic cause of corneal endothelial dis-
ease(s) in the large British kindred and the Czech families,
we undertook a sequential genetic approach with parallel
and integrated investigations.
Genetic Analysis of Family BR1
To refine the locus in the extended pedigree, we genotyped
microsatellite markers and SNPs in eight affected individ-
uals from different branches of the family (individuals
V:20, VI:2, VI:7, VI:17, VI:24, VII:3, VII:7, and VII:13;
Figure 1A). The disease interval was refined from a
2.7 Mb region to a 1.3 Mb region at chr20: 17,641,482–
18,949,130, which encompasses 46 annotated transcripts
(Table S1 and Figure 3).
We then used a dense chromosome-20-specific array to
performCGH on an affected individual (VII:13) to evaluate
potential CNVs at this locus. This approach did not iden-
tify any potentially disease-associated CNVs (data not
shown). Next, we performed WES for two affected individ-80 The American Journal of Human Genetics 98, 75–89, January 7, 20uals, VII:13 and VI:5 (Figure 1A). Given the apparent auto-
somal-dominant inheritance pattern of disease within the
family, we assumed that the causal disease variant would
be present in the heterozygous state, shared between the
two distantly related affected individuals, and given the
rarity of the condition, likely to have a minor allele fre-
quency (MAF) < 0.5% in the ExAC database. Filtering the
WES data according to these assumptions left only one
rare non-synonymous heterozygous variant that was
shared between the two affected individuals (Table S2).
The identified missense variant, c.1540A>C (p.Ile514Leu),
is on chromosome 20 in DZANK1 (GenBank:
NM_001099407), which encodes a predicted transcription
factor of undetermined function. This variant is located
within our refined CHED1 locus and was experimentally
verified to segregate with disease in the extended pedigree
by Sanger sequencing. The variant was identified in 5/
66,682 ethnically matched European alleles, and in silico
analysis of this variant predicted that it is likely to be a
benign polymorphism (Table S2). We further analyzed
theWES data with ExomeDepth to identify any potentially
causative exonic CNVs that are shared between the two
affected individuals and that might have been missed by
dense array CGH analysis specific to chromosome 20.20
No potentially deleterious small indels or CNVs were iden-
tified within genes in the disease interval on chromosome
20 or in any known genes related to corneal dystrophies.
Given that no variants likely to be associated with dis-
ease were identified by a CGH or WES approach, we
next performed WGS on DNA samples from two affected
individuals (VII:3 and VI:24) and an unaffected first-de-
gree relative (VI:22, age 44 years), for filtering purposes,
to explore the possibility that the causal mutation might
be in an intragenic or regulatory region within the refined
locus in chr20: 17,641,482–18,949,130 (Figures 1A and 3).
First, we filtered our WGS datasets to exclude all common
variants that have a MAF > 0.5% within the linked region
and that are present in the 1000 Genomes (Ensembl API
version 78), ExAC, UK10K, and GoNL datasets, as well
as a University College London (UCL) cohort comprising
a further 100 WGS datasets (UCL-WGS). We then
removed all variants present in unaffected individual
VI:22 or in a further eight WGS unrelated samples that
were sequenced via the same methods at the same time
for other purposes. Using this approach, we found that
both affected individuals share 19 variants in the refined
locus (chr20: 17,641,482–18,949,130) in the heterozygous
state (Table 1). These include the DZANK1 variant (identi-
fied previously via WES), 11 intergenic variants of un-
known significance, five deep intronic variants, a variant
located within an annotated non-protein-coding tran-
script (C20orf78), and a unique variant within the defined
promoter region of OVOL2: g.18057974_18057995dup
(c.339_361dup) (Table 1). This heterozygous duplica-
tion, located within the OVOL2 promoter, fully segregates
with disease in the family (21 affected and 12 unaffected
first-degree relatives; Figure 1A) and is absent in 20916
Figure 3. Schematic Representation of the Overlapping Loci, Conservation of the OVOL2 Promoter, and Relative Position of the Four
Mutations
(A) Overlapping disease-associated loci on 20p for the Czech familial cohort12 and the refined region in family BR1 (Figure S1).
(B) Annotated transcripts within the linked regions.
(C) Schematic illustration of OVOL2, which comprises four exons and encodes a 275 aa protein.
(D) ClustalW2multiple alignment of the promoter region of 11OVOL2 orthologs indicates the position of the fourmutations identified.
The following orthologs were used for the alignment: Homo sapiens (Ensembl: ENSG00000125850), Pan troglodytes (Ensembl:
ENSPTRG00000013280), Pongo abelii (Ensembl: ENSPPYG00000010732), Callithrix jacchus (Ensembl: ENSCJAG00000005049), Mus
musculus (Ensembl: ENSMUSG00000037279), Rattus norvegicus (Ensembl: ENSRNOG00000006850), Canis familiaris (Ensembl:
ENSCAFG00000005453), Equus caballus (Ensembl: ENSECAG00000007899), Pteropus vampyrus (Ensembl: ENSPVAG00000001140),
Dasypus novemcinctus (Ensembl: ENSDNOG00000025067),Monodelphis domestica (Ensembl: ENSMODG00000005504), and Xenopus tro-
picalis (Ensembl: ENSXETG00000024897). The alignment illustrates the conservation of a 145 bp promoter region in which the four
disease-associated mutations were identified (mutated base pairs are highlighted in red and boxed). The transcription start site is indi-
cated with an arrow. Mutations are annotated in accordance with the OVOL2 cDNA sequence (GenBank: NM_021220; Ensembl:
ENST00000278780), and þ1 represents the A of the ATG translation initiation codon.ethnically matched white British control samples (Sanger
sequencing).
Genetic Analysis of Czech PPCD1-Affected Families
Inparallel,we independently investigated the genetic cause
of disease in 16 Czech PPCD1-affected families (Figure 1B),
12 of which were previously shown to share an ancestral
PPCD1 disease haplotype at chr20: 17,335,789–
19,665,902 (Figure 3A).12 DNA from an affected individual
was analyzed by array CGH using a dense chromosome-20-
specific array. Furthermore, DNA from three additional
affected individuals was analyzed with an Affymetrix
Genome-WideHuman SNPArray 6.0. Neither independent
method revealed any CNVs within the disease locus.12
Next, we performedWES by using pooled DNA from ten
affected individuals from the Czech familial cohort (high-The Alighted in Figure 1B: IV:3 and V:5 from family C1, IV:8 and
V:9 from family C2, III:5 from family C3, IV:6 from family
C6, IV:1 from family C9, III:1 from family C11, IV:6 from
family C13, and II:3 from family C25). Given the apparent
autosomal-dominant mode of inheritance, we filtered the
data under the assumption that the causal disease variant
would be present in the heterozygous state in all ten
affected individuals and that the casual variant would
have a MAF < 0.5% in the ExAC Browser. On the basis of
these assumptions, no rare non-synonymous exonic het-
erozygous variants were found to be shared among the
analyzed affected individuals.
Given the possibility that a shared variant could be
missed by the WES pooling strategy or that the variant
might lie within a non-coding or regulatory region, we em-
ployed a targeted resequencing approach with a custommerican Journal of Human Genetics 98, 75–89, January 7, 2016 81
Table 1. Rare Heterozygous Variants within the Refined Locus, Chr20: 17,641,482–18,949,130, Identified by WGS in Family BR1
Variant
No.
Coordinates
(hg38)
Reference
Allele Observed Allele
Closest
Transcript Location dbSNP
Allele Count / Total Alleles Screened
1000G UK10K GoNL ExAC
UCL
WGS
1 18,057,973 A ACCGGTTCCGGC
GGCCGGGGCTG
OVOL2 promotor – NI NI NI NI NI
2 18,112,700 T A PET117 intergenic rs556855465 2/5,008 4/7,562 NI NI NI
3 18,114,422 A G PET117 intergenic rs560139714 NI NI 1/998 NI NI
4 18,119,439 A G PET117 intergenic rs563340932 NI NI 1/998 NI NI
5 18,124,502 TAGA T PET117 intergenic – NI NI NI NI NI
6 18,189,275 CT C CSRP2BP intergenic – NI 1/7,562 NI NI NI
7 18,189,278 C T CSRP2BP intergenic rs772649261 NI NI NI NI NI
8 18,240,797 G A CSRP2BP intergenic rs552441504 5/5,008 NI 7/998 NI NI
9 18,273,229 G A ZNF133 intergenic rs184537558 5/5,008 NI NI NI NI
10 18,292,765 C T ZNF133 deep intronic rs542530373 NI NI 1/998 NI NI
11 18,319,195 A G ZNF133 intergenic rs530751423 NI NI 1/998 NI NI
12 18,379,703 G A LINC00851 deep intronic rs558852368 2/5,008 NI NI NI NI
13 18,396,543 T G DZANK1 missense rs560809093 NI NI 1/998 5/120,650 NI
14 18,476,283 G A POLR3F deep intronic rs537806334 NI NI 1/998 NI NI
15 18,646,498 G A DTD1 deep intronic rs532426738 NI NI 1/998 NI NI
16 18,784,373 C A DTD1 intergenic rs570664591 NI NI 1/998 NI NI
17 18,810,051 G A C20orf78 non-coding
transcript
rs543631581 NI NI 1/998 NI NI
18 18,818,189 T C C20orf78 deep intronic rs566681725 NI NI 1/998 NI NI
19 18,851,016 C T C20orf78 intergenic rs550023958 NI NI 1/998 NI NI
WGS datasets generated for affected individuals VII:3 and VI:24 were filtered for removal of (1) all variants located outside the refined locus, (2) all variants with a
MAF> 0.5% in the publically available 1000G, UK10K, GoNL, and ExAC datasets and in a UCL cohort of 100WGS datasets (UCL WGS), and (3) variants present in
unaffected family member VI:22 and a further eight unrelated and unaffected WGS samples that were sequenced at the same time. Abbreviations are as follows:
1000G, 1000 Genomes Project; deep intronic, more than 100 bp from a defined intron-exon boundary; ExAC, Exome Aggregation Consortium; GoNL, Genomes
of the Netherlands; and NI, not identified.sequence capture designed to target the mapped interval
(chr20: 17,335,789–19,665,902) in the Czech families
(Figure 3). DNA samples for one affected individual
(V:11) and one unaffected individual (V:10, age 30 years)
from family C2 were selected for targeted re-sequencing.
We filtered annotated sequence data to exclude (1) variants
present in the unaffected individual and (2) variants with a
MAF > 0.5% in the 1000 Genomes, ExAC, UK10K, and
GoNL datasets, as well as an additional 108 UCL-WGS sam-
ples. Because of relatively poor coverage in some of the
target region, we also performed WGS for one affected
DNA sample (individual V:11 from family C2) to ensure
that all variants were represented in these datasets. Next,
we refined the list of variants to those present on the
affected haplotype by directly sequencing each variant in
the married-in unaffected father (individual IV:17 from
family C2). This reduced the number of affected haplotype
variants within the PPCD1 locus (chr20: 17,335,789–
19,665,902) to 18, including 12 intergenic variants of un-
known significance, five deep intronic variants, and a
unique variant within the defined promoter region of82 The American Journal of Human Genetics 98, 75–89, January 7, 20OVOL2: g.18058004A>G (c.370T>C) (Table 2). The
c.370T>C variant segregates with disease in all 16 pedi-
grees shown in Figure 1B (it is present in 75 affected and
absent in 21 unaffected first-degree relatives) and is absent
in 216 ethnically matched Czech control samples. Strik-
ingly, this OVOL2 variant is located 9 bp upstream of the
duplication identified in the OVOL2 promoter in family
BR1 (Figure 3). Notably, no variants likely to be associated
with disease were identified in DZANK1.
Using the VEP, we analyzed all unique variants in
CHED1 and PPCD1 (Tables 1 and 2) to determine whether
any are located in potentially functional regulatory re-
gions. Only two variants were found to be situated within
regulatory regions, and both are located within the OVOL2
promoter (Tables 1 and 2). No other unique variants were
found in predicted regulatory regions.
Screening OVOL2 as a Candidate Gene in Genetically
Unsolved PPCD Cases
To determine whetherOVOL2mutations could account for
disease in further cases of PPCD, we screened eight British16
Table 2. Rare Heterozygous Variants within the Linked PPCD1 Region, Chr20: 17,335,789–19,665,902, Identified by Targeted Re-sequencing and WGS in Individual V:11 from Family C2
Variant
No. Coordinates (hg38)
Reference
Allele
Detected via Targeted
Re-sequencing
Detected
via WGS
Observed
Allele
Closest
Transcript Location dbSNP
Allele Count / Total Alleles Screened
1000G UK10K GoNL ExAC UCL WGS
1 17,779,178 T not covered yes C BANF2 Intergenic – NI NI NI NI NI
2 17,962,621 T yes yes TTCGGGGG
AGGGGGG
SNX5 deep intronic – NI NI NI NI NI
3 18,010,425 T not covered yes C OVOL2 intergenic rs62206463 NI NI NI NI NI
4 18,058,004 A yes yes G OVOL2 promoter – NI NI NI NI NI
5 18,373,822 G yes yes A LINC00851 intergenic – NI NI NI NI NI
6 18,504,053 T yes yes G SEC23B intergenic – NI NI NI NI NI
7 18,800,653 T yes yes C NR_026885 intergenic – NI NI NI NI NI
8 18,831,605 T yes yes C C20orf78 intergenic – NI NI NI NI NI
9 18,836,917 A yes yes G C20orf78 intergenic – NI NI NI NI NI
10 18,863,686 G not covered yes C C20orf78 intergenic rs148906570 10/5,008 NI NI NI NI
11 18,870,484 C not covered yes G C20orf78 intergenic rs150426313 10/5,008 60/7,562 9/998 NI NI
12 18,937,206 C yes yes G C20orf78 intergenic – NI NI NI NI NI
13 18,950,428 C not covered yes T C20orf78 intergenic – NI NI NI NI NI
14 19,140,530 G yes yes A SLC24A3 intergenic – NI NI NI NI NI
15 19,325,002 A yes yes G SLC24A3 deep intronic – NI NI NI NI NI
16 19,331,987 C yes yes T SLC24A3 deep intronic rs537549121 9/5,008 2/7,562 NI NI NI
17 19,601,355 C yes yes A SLC24A3 deep intronic – NI NI NI NI NI
18 19,637,683 A yes yes G SLC24A3 deep intronic – NI NI NI NI NI
Next-generation sequencing datasets generated for affected individual V:11 were filtered for removal of (1) all variants located outside the refined locus, (2) all variants with a MAF > 0.5% in the publically available 1000G,
UK10K, GoNL, and ExAC datasets and in a UCL cohort of 100 WGS datasets (UCL WGS), (3) all variants present in unaffected family member V:10 and identified by targeted re-sequencing, (4) variants present in eight
unrelated and unaffected WGS samples that were sequenced at the same time, and (5) variants present in the unaffected (married-in) father (IV:17) and identified by direct sequencing. Abbreviations are as follows:
1000G, 1000 Genomes Project; deep intronic, more than 100 bp from a defined intron-exon boundary; ExAC, Exome Aggregation Consortium; GoNL, Genomes of the Netherlands; and NI, not identified.
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and Czech probands with genetically unsolved PPCD by
bi-directional Sanger sequencing of the entire coding re-
gion, intron-exon boundaries, and 1.8 kb of the promoter
region. No mutations were identified within the coding re-
gion or exon-intron splice sites of the gene; however, we
identified two unique variants in this cohort within the
highly conserved proximal promoter region of OVOL2.
These variants were found to be located in proximity to
the disease-associated variants identified byWGS in family
BR1 and the founder Czech families (Figure 3D).
One individual (IV:2) from family BR2 (Figure 1C) was
available for clinical examination and genetic testing. She
reported an autosomal-dominant family history
(Figure 1C) and has had poor vision from corneal opacity
since childhood. Her phenotype could not be re-assessed
because her right eye had had multiple corneal graft
procedures and glaucoma drainage surgery and because
the left eye had been enucleated. A heterozygous
variant, c.274T>G (g.18057908A>C), located within the
OVOL2 promoter was identified by direct Sanger
sequencing (Figure 1C and Figure 3D). This variant is absent
in 209 ethnically matched control samples (direct Sanger
sequencing) and the1000GenomesandUCLWGSdatasets.
Two individuals (III:3 and IV:2) from family BR3
(Figure 1D) were available for clinical examination and
genetic evaluation. They have an inherited autosomal-
dominant form of PPCD, which is less severe than that
in families BR1 and BR2. Both individuals showed mild
vision loss with a best-corrected LogMar visual acuity of
0.2, and neither has glaucoma or has required corneal sur-
gery. The individuals showed bilateral opacities at the level
of the Descemet membrane and an irregular posterior
corneal surface with peripheral adhesions between the
iris and cornea (one individual also showed a distorted
iris in one eye) (Figure 2E). This phenotype is more similar
to that in the Czech families (C1–C14, C25, and C30) than
that in families BR1 and BR2. Direct Sanger sequencing
of the OVOL2 promoter in individual IV:2 (Figure 1D)
identified a unique heterozygous variant, c.307T>C
(g.18,057,941A>G), within the highly conserved region
(Figure 3D). This variant was also found in the heterozy-
gous state in her affected mother (individual III:3) but is
absent from 209 ethically matched control samples
(Sanger sequencing) and the 1000 Genomes and UCL-
WGS datasets.
OVOL2 as a Candidate Gene for PPCD1 and/or CHED1
OVOL2 encodes ovo-like zinc finger 2, a C2H2 zinc-finger
transcription factor, and we considered it to be an excellent
candidate gene for PPCD1 and/or CHED1. The established
PPCD-associated gene ZEB1 encodes a zinc-finger tran-
scription factor that drives epithelial-to-mesenchymal
transition (EMT) via repression of genes, including CDH1
(E-cadherin [MIM: 192090]).32 OVOL2 induces mesen-
chymal-to-epithelial transition (MET) via direct repression
of ZEB1 expression, and the two genes operate in a regula-
tory feedback loop that controls cellular plasticity.3384 The American Journal of Human Genetics 98, 75–89, January 7, 20We sought to identify where OVOL2 is expressed in the
adult human cornea by RT-PCR using a variety of corneal
tissues and cultured cells. OVOL2 expression was detected
in full-thickness corneal tissue, but we were unable to
detect expression in adult human endothelial cells
derived directly from control tissue, cultured cells
expanded from adult corneal endothelial tissue, or an
immortalized cell line of human corneal endothelial
origin (Figure S1). Interestingly, interrogation of RNA-
seq data for human corneal endothelial samples also
confirmed that OVOL2 was not expressed in fetal (16–
18 weeks of gestation) or adult corneal endothelium.34
These are important data because they demonstrate that
OVOL2 is not normally expressed in the tissue of interest.
Furthermore, OVOL2 expression was absent from
cultured stromal fibroblasts (Figure S1). OVOL2 expres-
sion has previously been detected in epithelial tissues,
including skin, kidney, and the germinal epithelium of
the testis.35 Similarly, we detected OVOL2 expression in
a human corneal epithelial culture derived from limbal
epithelial stem cells and in a spontaneously immortalized
human corneal epithelial cell line with progenitor-like
characteristics36 (Figure S1). These data support the hy-
pothesis that mutations in the OVOL2 promoter are likely
to exert a gain-of-function effect as a result of inappro-
priate ectopic expression in the developing or adult
corneal endothelium.
Disease-Associated Mutations Alter Activity of the
OVOL2 Promoter
Given that PPCD3 is caused by presumed haploinsuffi-
ciency of ZEB1,10,37 we hypothesized that the mutations
identified in the OVOL2 promoter might cause disease
through dysregulated OVOL2 expression, potentially by a
mechanism leading to overexpression of OVOL2 and
reduced ZEB1 expression.33,38
The four mutations cluster within an evolutionary
conserved region of the OVOL2 proximal promoter region
(between 370 and 274 bp upstream of the translation
start site: Figure 3D). Typically, such regulatory regions up-
stream of core promoter sequences contain multiple tran-
scription-factor-specific binding motifs that cooperatively
stimulate transcriptional activity of a given gene.39 Initial
interrogation of chromatin immunoprecipitation
sequencing (ChIP-seq) data published as part of the
ENCODE dataset revealed that it is a transcriptionally
active region with binding sites for multiple transcription
factors, including FOXA1, FOXA2, NRF1, SP1, CTBP2,
and EP300 (Figure 4A). We therefore employed the
in silico prediction programs Alibaba 2.1 andMatInspector
to test for potential altered transcription factor binding
when the four mutations are introduced; compared to
the wild-type, all four variants independently resulted in
altered predicted transcription factor binding sites (Ta-
ble 3). Interestingly, interrogation of RNA-seq data for hu-
man adult and fetal corneal endothelial cells revealed that
the majority of these transcription factors were expressed16
Figure 4. Functional Analysis of the OVOL2 Promoter
(A) OVOL2mutations are located within a transcriptionally active region of the promoter. Interrogation of publically available ChIP-seq
data released as part of the ENCODE project demonstrates that multiple transcription factors, including FOXA1, FOXA2, NRF1, SP1,
CTBP2, and EP300, bind the region encompassing all OVOL2 disease-associated mutations.
(B)Mutations in theOVOL2 promoter cause an increase in gene expression in vitro. A dual-luciferase reporter assay was used for assessing
the impact of disease-associated mutations on the activity of theOVOL2 promoter. HEK293 cells were co-transfected with pRL-CMV (Re-
nilla luciferase) and pGL3-Basic (firefly luciferase) containing 1,824 bp of the wild-type or respective mutantOVOL2 promoter sequence.
The ratio of firefly to Renilla luciferase activity was calculated for all samples. Wild-type data were normalized to 1, and the relative lucif-
erase activity in all other samples is expressed in relation to the wild-type data. All mutations investigated significantly increased the
relative luciferase activity. Data represent a minimum of three independent experiments with triplicate measurements. Error bars repre-
sent5 1 SD. p values were calculated by one-way ANOVA (***p % 0.001).in the tissue of interest and, therefore, could represent bio-
logically relevant transcription factors.
Next, we experimentally tested the sequence variants
in vitro for altered promoter activity by performing a
dual luciferase reporter assay. It has been previously estab-
lished that 1.8 kb of the murine Ovol2 promoter is suffi-
cient to drive expression of luciferase in HEK293T cells.40
Given that the respective syntenic regions share a high
level of homology (Figure 3D), we cloned an equivalent
1,824 bp fragment of wild-type sequence and the four
respective mutant OVOL2 promoter sequences into the
promoterless firefly luciferase expression vector pGL3-
Basic.
Our working hypothesis is that dysregulation of OVOL2
occurs during development. Given that the corneal endo-
thelium is derived from the neural crest during embryonicThe Adevelopment, we wanted to use an appropriate cell line for
the luciferase assay. Despite their name, HEK293 cells most
likely originate from an embryonic adrenal gland precursor
structure41 and have been shown to express a number of
neuronalmarkers.42 This suggests that they derive from ad-
renal medulla progenitors, which are themselves derived
from the ectoderm of the neural crest. Furthermore, we
determined that OVOL2 is expressed in the HEK293 cell
line, suggesting that appropriate regulatory transcription
factors might also be expressed (Figure S1). HEK293 cells
were co-transfected with each OVOL2 promoter construct
in combination with pRL-CMV for normalization. The
1,824 bp wild-type sequence was sufficient to drive expres-
sion of firefly luciferase, and each of the four respective
mutants was independently found to significantly increase
promoter activity in vitro (p % 0.001) (Figure 4B).merican Journal of Human Genetics 98, 75–89, January 7, 2016 85
Table 3. In Silico Analysis of Disease-Associated Variants in the OVOL2 Promoter
TF
Predicted Effect of OVOL2 Promoter Variants on TF Binding
Relative Abundance of
Transcripts, Encoding the
TF of Interest, Detected in
the Corneal Endothelium
by RNA-Seq (RPKM)
c.339_361dup
(Family BR1)
c. 370T>C
(Families C1–C14,
C25, and C30)
c. 274T>G
(Family BR2)
c. 307T>C
(Family BR3) Adult Fetal
ELK1 TF site gaineda TF site gaineda,b TF site gaineda – 14.01 17.42
GRHL1 TF site gaineda – – – 0.98 0.04
SLC2A4RG TF site gaineda TF site gaineda – – 11.36c 20.46c
FLI1 TF site gaineda – – – 7.85 1.79
ZNF239 – TF site gaineda – – 2.18 4.30
REL – TF site gaineda – – 2.17 1.00
ZNF143 – – TF site losta – 12.06 7.54
DMRTA2 – – – TF site gaineda 0.65 0.02
RABL6 – – – TF site gaineda 14.98c 10.10c
RFX3 – – – TF site gaineda 2.39 5.07
T – – – TF site losta 0.00 0.01
SP1 TF site gainedb TF site gainedb – – 12.52 17.53
EGR1 TF site gainedb – – – 134.09 84.08
ATF2 – – – TF site gainedb 11.78 13.26
SRF – – TF site gainedb – 21.42 16.48
ETS1 – – TF site lostb – 10.92 9.01
OVOL2 variants are annotated in accordance with GenBank: NM_021220, andþ1 represents the start of translation. Human corneal endothelial RNA-seq reads for
three adult and two fetal (16- to 18-week-old) samples (study SRP01140 from ArrayExpress) were aligned to the human reference genome (NCBI Genome
build 38; GCA_000001405.15_GRCh38 without alternate contigs) with STAR v.2.5.0. Abbreviations are as follows: RKPM, reads per kilobase per million mapped
reads; and TF, transcription factor.
aMatInspector, which is a software tool that utilizes a large library of matrix descriptions for transcription factor binding sites to locate matches in DNA sequences.
bAliBaba 2.1, which is a program that predicts transcription factor binding sites in an unknown DNA sequence by utilizing binding sites collected in the public
database TRANSFAC.
cRKPM values also encompass flanking transcripts.Discussion
The genetic cause of PPCD1 and CHED1 has proved elusive
because conventional gene-screening strategies have failed
to investigate potential promoter variants as the cause of
corneal endothelial dystrophies linked to chromosomal re-
gion 20p11.23. In the promoter of OVOL2, we have identi-
fied four mutations that segregate with disease in over 100
affected individuals. Our data demonstrate that CHED1
and PPCD1 are allelic conditions representing extremes
of disease severity, and we support future use of the
nomenclature PPCD1 to represent this spectrum of corneal
endothelial dystrophies.1 The more severely affected indi-
viduals (as described for family BR1) have been symptom-
atic since birth and displayed corneal haze by 1 year of age.
The majority have now had surgery in the form of corneal
transplantation, which has often had a poor outcome
requiring multiple grafts and caused a tendency for visual
loss from corneal opacity and secondary glaucoma. In
many cases, visual deprivation in childhood has led to86 The American Journal of Human Genetics 98, 75–89, January 7, 20amblyopia and nystagmus. A similarly severe phenotype
(early visual loss, keratoplasty, and glaucoma) has also
been reported in a further family linking to the same
locus.7
The mature corneal endothelium consists of a mono-
layer of regular hexagonal cells that function both as a bar-
rier and as a pump to maintain corneal deturgescence.
Endothelial cells have limited proliferative capacity, and
cells are lost at a rate of 0.6% per year, resulting in
decreasing cell density.43,44 Although PPCD1 primarily af-
fects corneal endothelial cells, we were unable to detect
OVOL2 expression in any adult corneal-endothelial-
derived tissue or cell line tested.OVOL2 plays an important
role during development, and Ovol2/ mice die at embry-
onic day 10.5 (corresponding with approximately day 28
of human embryonic development). Prior to this, they
fail to develop a precursor of the corneal ectoderm (the op-
tic eminence) and demonstrate impaired neural crest cell
survival and migration.45 In the developing human em-
bryo, the corneal endothelium is derived from neural crest16
cells that are located at the boundary of the neural plate
and surface ectoderm.46 These neural crest cells undergo
EMTandmigrate to developing tissues, including the ante-
rior segment, where they differentiate to form the corneal
endothelial monolayer by the eighth week of gesta-
tion.47,48 Publically available RNA-seq data derived from
16- to 18-week-old human fetal corneal endothelial sam-
ples are also negative for OVOL2 expression.34
We have demonstrated that the mutations identified in
the OVOL2 promoter dysregulate OVOL2 expression, and
we suggest that this will affect the function of downstream
genes and pathways, including potential transcriptional
regulation of the PPCD3-associated gene ZEB1. Our data
imply that upregulation of OVOL2 expression, by the
introduction of functional cryptic cis-acting transcription
factor binding sites, is the disease mechanism. We suggest
that the mutations induce inappropriate ectopic expres-
sion in the corneal endothelium; however, it is currently
not clear whether this occurs during development or in
the adult endothelium, or indeed both.45 It also remains
plausible that OVOL2 is expressed in vivo at deve-
lopmental stages not currently investigated and that the
promoter mutations identified could lead to loss, or down-
regulation, of OVOL2 at a crucial time point in eye devel-
opment. We speculate that the timing and severity of
this inappropriate expression will be mutation dependent,
given that different transcription factors (activators or re-
pressors) might bind to the cryptic cis-acting promoter
sequence elements created by the different mutations. In
support of this, we observed differences in disease charac-
teristics and severity as a result of the different mutations.
At the severe end of the disease spectrum is a congenital
disorder that affects corneal endothelial development by
leading to a loss of endothelial cells (family BR1), whereas
in the milder Czech families, focal multilayering of endo-
thelial cells49 (Figure 2H) and cellular ‘‘epithelialization’’
with increased expression of several epithelial keratins,
predominantly KRT7 and KRT19, are characteristic of the
disease.30 Additionally, malformation of the anterior
segment is associated with two of the four mutations iden-
tified (families BR2 and BR3).
Aberrant OVOL2 expression levels are likely to have a
range of downstream consequences; however, given
that it is a known direct repressor of ZEB1 (an established
PPCD-associated gene), it seems plausible that dy-
sregulation of this OVOL2-ZEB1 regulatory feedback
loop is most likely relevant to the mechanism of patho-
genesis.33 Increased transcriptional repression of ZEB1
expression due to overexpression of OVOL2 would be
expected to have a similar outcome on the variety of
reported PPCD3-associated nonsense, frameshift, and
deletion mutations that result in ZEB1 haploinsuffi-
ciency.10,37
To address the potential disease mechanism, or mecha-
nisms, leading to the range of corneal endothelial dystro-
phy phenotypes observed as a consequence of OVOL2
promoter mutations, it will be important to accuratelyThe Amodel corneal disease in an appropriate cell or animal
model. Identification of the diseased cell populations inap-
propriately expressing OVOL2, and transcription factors
that bind as a result of the mutations, most likely in a
cell-dependent context, will be an important next step to-
ward understanding the perturbed regulatory pathways
leading to disease.Supplemental Data
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